2026年1月23日,株価目標が変更され,セクター見通しの変化に伴い,主要企業の修正が混じった. On January 23, 2026, stock price targets shifted, with mixed revisions across major firms amid changing sector outlooks.

2026年1月23日,アナリストの価格目標が主要株に変化した.アボット研究所は125ドルから144ドルの目標で複数の下方修正に直面し,abrdn,Adient,Allison Transmission,Associated Banc,American Axle,Banc of California,BancFirst,Barclays,Biogen,Caterpillarはさまざまな企業からアップグレードを受けた. On January 23, 2026, analyst price targets shifted across major stocks: Abbott Laboratories faced multiple downward revisions, with targets ranging from $125 to $144, while abrdn, Adient, Allison Transmission, Associated Banc, American Axle, Banc of California, BancFirst, Barclays, Biogen, and Caterpillar received upgrades from various firms. ARMは大幅な削減を遂げ,Booking,B&M European Value Retail,Broadridgeも下落した. ARM saw a significant cut, and Booking, B&M European Value Retail, and Broadridge were also lowered. 全体として、センチメントはまちまちで、企業は異なるセクター見通しの中で目標を調整しています。 Overall, sentiment remained mixed, with firms adjusting targets amid varied sector outlooks.